Novo Nordisk A/S
NYSE: NVO
$74.01
-$0.33 (-0.4%)
Closing Price on June 18, 2025
NVO Articles
The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have something genuinely...
Published:
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and diabetes treatments. LLY stock has delivered exponential returns from 2018...
Published:
Last Updated:
Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market agrees, sending shares of PLTR stock some 342% higher over the past year, far...
Published:
Last Updated:
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY) has become the industry leader in a class of drugs called...
Published:
The Dow Jones is one of Wall Street’s most iconic benchmarks and it tracks 30 of America’s largest companies. It was made over 128 years ago but is still relevant and a crucial barometer of the...
Published:
According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S. increasing their year-over-year...
Published:
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,...
Published:
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Published:
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Published:
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
Published:
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and...
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Published:
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published:
